#CLDN182
LightNews LightNews
tamedoncol.bsky.social
A large retrospective cohort shows CLDN18.2 expression does not influence outcomes of first‑line immunochemotherapy in HER2‑negative, pMMR, PD‑L1 CPS≥1 metastatic gastric/GEJ cancer.
🔗 buff.ly/rdAewUh
#GastricCancer #Immunotherapy #CLDN182 #Biomarkers
March 7, 2026 at 8:01 AM
dengyuemedicine.bsky.social
China’s NMPA Approves Zolbetuximab for Injection

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#Zolbetuximab
#Wiluyi
#CLDN182
#GastricCancer
#GEJCancer
#Astellas
#NMPAApproval
#Oncology
#TargetedTherapy
#MonoclonalAntibody
November 14, 2025 at 9:46 AM
abangelabs.bsky.social
SMC accepts zolbetuximab plus chemotherapy for CLDN18.2-positive HER2-negative advanced gastric or GEJ adenocarcinoma https://www.mattheneus.com/editorial/smc-zolbetuximab-vyloy-acceptance-cldn182-her2-negative-gastric-gej-2026-03-04 #HTA #HealthEconomics #EvidenceSynthesis
March 4, 2026 at 8:21 PM
medcitynews.com

Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug
https://medcitynews.com/2025/05/astellas-pharma-cancer-drug-evopoint-cldn182-gastrointestinal-adc/
Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug
Astellas Pharma gets global rights to an Evopoint Biosciences antibody drug conjugate that targets Claudin 18.2. Last year, Astellas’s antibody drug Vyloy became the first FDA-approved therapy for this target.
medcitynews.com
May 31, 2025 at 4:01 AM